3,350,000 Shares in Amicus Therapeutics, Inc. (NASDAQ:FOLD) Acquired by Vestal Point Capital LP

Vestal Point Capital LP purchased a new position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 3,350,000 shares of the biopharmaceutical company’s stock, valued at approximately $31,557,000. Amicus Therapeutics makes up 1.9% of Vestal Point Capital LP’s holdings, making the stock its 22nd biggest holding. Vestal Point Capital LP owned about 1.12% of Amicus Therapeutics at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in FOLD. Wellington Management Group LLP lifted its stake in Amicus Therapeutics by 18.8% during the fourth quarter. Wellington Management Group LLP now owns 28,461,994 shares of the biopharmaceutical company’s stock worth $268,112,000 after purchasing an additional 4,497,950 shares during the last quarter. Norges Bank bought a new stake in Amicus Therapeutics during the fourth quarter worth $29,033,000. Orbimed Advisors LLC lifted its stake in Amicus Therapeutics by 300.7% during the fourth quarter. Orbimed Advisors LLC now owns 2,285,400 shares of the biopharmaceutical company’s stock worth $21,528,000 after purchasing an additional 1,715,100 shares during the last quarter. Rock Springs Capital Management LP lifted its stake in Amicus Therapeutics by 107.9% during the fourth quarter. Rock Springs Capital Management LP now owns 2,599,425 shares of the biopharmaceutical company’s stock worth $24,487,000 after purchasing an additional 1,349,145 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its stake in Amicus Therapeutics by 174.1% during the fourth quarter. Renaissance Technologies LLC now owns 2,108,616 shares of the biopharmaceutical company’s stock worth $19,863,000 after purchasing an additional 1,339,316 shares during the last quarter.

Amicus Therapeutics Stock Performance

Shares of FOLD opened at $6.43 on Monday. The company has a debt-to-equity ratio of 2.01, a current ratio of 3.39 and a quick ratio of 2.42. The stock has a 50-day moving average of $7.37 and a 200-day moving average of $8.88. The company has a market cap of $1.98 billion, a PE ratio of -35.72, a P/E/G ratio of 1.51 and a beta of 0.64. Amicus Therapeutics, Inc. has a one year low of $5.81 and a one year high of $12.65.

Analyst Upgrades and Downgrades

FOLD has been the subject of several recent analyst reports. Needham & Company LLC restated a “hold” rating on shares of Amicus Therapeutics in a research note on Thursday, February 20th. Wells Fargo & Company dropped their price target on Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating for the company in a research note on Thursday, February 20th. StockNews.com downgraded Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, May 5th. UBS Group increased their price objective on Amicus Therapeutics from $21.00 to $22.00 and gave the company a “buy” rating in a report on Friday, May 2nd. Finally, The Goldman Sachs Group decreased their price objective on Amicus Therapeutics from $12.00 to $9.00 and set a “neutral” rating for the company in a report on Friday, May 2nd. Four analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, Amicus Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $16.22.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.